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Abstract
Glucocorticoid negative feedback of the hypothalamus-pituitary-adrenal axis is mediated in part by direct repression of
gene transcription in glucocorticoid receptor (GR) expressing cells. We have investigated the cross talk between the two
main signaling pathways involved in activation and repression of corticotrophin releasing hormone (CRH) mRNA expression:
cyclic AMP (cAMP) and GR. We report that in the At-T20 cell-line the glucocorticoid-mediated repression of the cAMP-
induced human CRH proximal promoter activity depends on the relative timing of activation of both signaling pathways.
Activation of the GR prior to or in conjunction with cAMP signaling results in an effective repression of the cAMP-induced
transcription of the CRH gene. In contrast, activation of the GR 10 minutes after onset of cAMP treatment, results in a
significant loss of GR-mediated repression. In addition, translocation of ligand-activated GR to the nucleus was found as
early as 10 minutes after glucocorticoid treatment. Interestingly, while both signaling cascades counteract each other on
the CRH proximal promoter, they synergize on a synthetic promoter containing ‘positive’ response elements. Since the
order of activation of both signaling pathways may vary considerably in vivo, we conclude that a critical time-window exists
for effective repression of the CRH gene by glucocorticoids.
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Introduction
Corticotropin releasing hormone (CRH) is a pivotal signaling
molecule in the regulation of the stress response. This neuropep-
tide is expressed at high levels in the hypothalamus, from where it
coordinates the hormonal and autonomic response to stress, and
the central nucleus of the amygdala, where it plays a crucial role in
regulating anxiety. Regulation of the expression of CRH is
therefore thought to be physiologically important in relation to
coping with stress. CRH gene regulation is a complex process that
involves multiple activating and repressing transcription factors
[1]. Among the often studied factors that can regulate CRH
expression are glucocorticoid hormones [2], which in a cell-
dependent manner either repress of stimulate the CRH gene. As
such, the CRH promoter can be considered a model gene for cell-
specific negative regulation of gene expression via glucocorticoids.
Cross-talk of intracellular signaling pathways is central to many
neuroendocrine control systems [3,4]. The expression and/or
secretion of the two main neuroendocrine secretagogues of the
hypothalamus-pituitary-adrenal axis (HPA axis) are both stimu-
lated by cAMP and suppressed by glucocorticoids, the end-
product of the HPA axis: hypothalamic CRH, as well as
adrenocorticotrophic hormone (ACTH) from anterior pituitary
corticotrophs [5–8]. At the molecular level, these signals are
represented by protein kinase A (PKA), the transcription factor
cAMP element-binding protein (CREB), and the GR, respectively.
The proximal promoter of the human corticotrophin releasing
hormone (hCRH) gene contains a canonical, functional cAMP
response element (CRE) and a negative glucocorticoid receptor
response element (nGRE) (fig. 1). Induction of the hCRH gene by
the PKA pathway is mediated by phosphorylation of CREB at
serine residue 133 [9,10]. In vivo,W o ¨lfl et al. showed that binding of
CREB to the canonical CRE located at the nucleotide position
2224 (upstream of exon 1) was specifically induced after activation
of the PKA pathway with forskolin [11]. Additionally, Kovacs et al.
demonstrated that in the hypothalamic parvocellular neurons of
rodents subjected to ether stress, CREB phosphorylation was
induced in a time course that parallels the increase of CRH
heteronuclear RNA levels [12].
In vitro, the At-T20 cell-line is a well-established model system for
studying glucocorticoid-induced repression of the hCRH proximal
promoter. Nested deletions and site-specific point mutations of the
CRE located at nucleotide 2224 resulted in a significant loss of
induction by cAMP, demonstrating that CREB binding is necessary
for the stimulation of the gene [13]. In parallel, electrophoretic
mobility shift assays (EMSA)identified a GR-binding site at position
nt 2249 that was indispensable for GR-mediated repression of the
cAMP-induced promoter. Internal deletion of the entire nGRE and
specific point mutationsresulted ina lossof repression bytheligand-
activated GR, indicating that DNA binding is essential for the
glucocorticoid-induced repression [14]. Of note: while we have
taken this nGRE-mode as working model, a separate series of
experiments did not find evidence for direct GR binding to the
CRH promoter, but rather suggested direct CREB-GR interactions
as the cause of GR-mediated reression [15].
The nGRE in the hCRH promoter is separated by as few as 25
bp with the canonical CRE, a distance that clearly permits
functional interactions at the promoter [16]. Since, in vivo the order
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may vary considerably, and this is known to affect responses at the
level of neuroendocrine secretion [17], we tested the hypothesis
that effective repression of the cAMP-induced hCRH proximal
promoter depends on the relative timing of GR activation in the
At-T20 cell-line.
Results
Dexamethasone pre- or simultaneous co-treatment with
FSK
FSK treatment led to a robust and progressive stimulation of the
CRH-promoter activity that was evident for luciferase induction
from 1 hour to at least 5 hours (fig. 2A). In line with previous
reports [14,18], simultaneous DEX co-treatment strongly sup-
pressed the FSK-induced stimulation of the hCRH-promoter
activity (fig. 2A). DEX co-treatment resulted in up to 75%
repression of the FSK-induced promoter activity after 3 hours
treatment (fig. 2B). To test our hypothesis that the order of
activation of both signaling cascades affects the level of GR-
mediated repression, we initiated the DEX treatment at different
time points prior to or after initiation of the 3-hours FSK
treatment (fig. 2C). We compared the DEX-induced repression in
the different groups to the simultaneous co-treatment group,
which was set at 100% repression. Two hours of DEX pre-
treatment resulted in a significantly increased repression, suggest-
ing that a slower mechanism requiring de novo protein synthesis is
responsible for the additional repression (data not shown).
Activation of the GR up to one hour prior to FSK treatment
did not affect the levels of repression (fig 2C, first three time
points). Of note, DEX treatment alone (0.1 mM) did not suppress
the basal activity of the CRH-promoter, indicating that basal
CRH drive is not governed by CREB/CRE dependent mecha-
nisms (data not shown).
Dexamethasone treatment applied after FSK
When DEX was applied after forskolin stimulation of the CRH
promoter, the time-window separating both treatments was of
great consequence for the level of repression (fig. 2C). A
10 minutes delay in the onset of DEX treatment relative to the
FSK treatment resulted in a loss of 20% repression. Strikingly, a
30 minutes delay resulted in a 50% loss of GR-mediated
repression, indicating the importance of the relative time of
treatment. Clearly, the reduced time of DEX exposure is not
proportional to the loss of GR-mediated repression pointing to a
‘GR resistance’. Because FSK treatment induces a progressive
increase of the CRH-luc promoter activity over a period of at least
5 hours (fig. 2A) we assume that FSK-induces binding of CREB to
the promoter over that period. However, the first hour following
FSK treatment is critical for the GR to mediate effective
repression.
To assess whether FSK treatment alters the translocation
properties of the GR to the nucleus, we quantified GR-
immunoreactivity in the different conditions. The data show that
DEX treatment induces maximal nuclear GR-immunoreactivity
(GR-ir) as early as 10 minutes after treatment (figure 3). No
difference in nuclear GR-ir was observed between the 10 and
30 minutes DEX treatment groups, suggesting that the ‘GR
resistance’ is not due to delayed translocation to the nucleus
(fig. 3A). In addition, FSK treatment did not influence transloca-
tion dynamics of the GR although it is known that PKA activation
can modulate the steroid sensitivity by enhancing DNA binding
properties of GR [19]. In sum, the translocation data provide
evidence that GR should be capable of modulating gene
transcription as early as 10 minutes after treatment and that
FSK treatment does not interfere with translocation related
mechanisms.
Promoter specificity
Posttranslational modification such as phosphorylation is known
to affect DNA binding properties, transcriptional activation and
stability of numerous nuclear receptors including GR [19].
Although translocation to the nucleus was not affected by FSK
treatment, we tested whether FSK influenced the transcriptional
activity of the GR in these cells. We measured the effect of FSK
and DEX co-treatment on a positively regulated promoter (a
Figure 1. Simplified representation of the hCRH-luc promoter and known response elements. Schematic representation of the
composite hCRH proximal promoter, as present in the reporter construct. Although only the known nGRE and CRE have been indicated, many
response elements have been identified within the used reporter construct, such as a functional estrogen response element half site [28], and several
putative AP1 sites [14,25]. In addition, some of the listed factors act on sequences that are not present in reporter construct [29].
doi:10.1371/journal.pone.0004327.g001
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treatment synergistically induced transcription on an exclusively
GRE-containing promoter compared to DEX treatment alone
(fig. 4). FSK treatment prior DEX treatment resulted in an
increased transcriptional activity of the GR. Likewise, the longer
the time of FSK co-treatment the higher the transcriptional
activity of the GR.
Discussion
The current data demonstrate that time-dependent interactions
between GR and cAMP/CREB can occur at the level of the CRH
gene, where these factors seem to functionally compete for the
same promoter. While similar interactions have been described for
the secretion of ACTH from the pituitary [17], we now show that
cAMP induced ‘GR-resistance’ occurs at the level of a single
promoter, and that it is not a global cellular phenomenon, but
gene-specific.
Using the nGRE that was reported to be functional in these cells
as a working model [14], the observed ‘primacy’ effect for
transcription factor action at the CRH promoter may be due to
the close proximity of the two response elements involved. The
spacing of the elements is such that it is unlikely that both GR and
CREB may bind simultaneously in an independent manner [16].
Sterical hindrance at the promoter due to the formation of larger
protein complexes may be responsible for the importance of
timing of stimuli. Alternatively, in view of the dynamic nature of
transcription factor-DNA interactions, CREB-mediated chroma-
tin remodeling events that disfavor GR-binding may account for
the decreased GR efficacy observed after prior cAMP elevations.
Interestingly, the analogous dependence of timing of both
cAMP and GR that exists for ACTH secretion [17], which
obviously is not linked to the activity of the exogenous reporter
plasmid, suggests that the phenomenon of time-dependence occurs
at multiple genes. Any gene regulated in a parallel manner will
allow better hypotheses as to the mechanism that is responsible for
the time dependent effects. POMC and CRH seem to depend on
the same coregulator molecule, namely SRC-1 [18,21]. In this
respect it would be of great interest to also study negative
regulation of the endogenous POMC gene in these cells under
similar conditions as were used for the CRH reporter construct.
Although numerous studies were devoted to understanding the
regulation of CRH gene expression in the paraventricular nucleus
of the hypothalamus, it is still a topic of debate whether the
activated-GR directly acts on the promoter region of the gene or
that different mechanisms are responsible for the repression of
CRH gene after stress. Bali et al. convincingly demonstrated in
organotypic slice cultures that the GR directly acts on the
paraventricular neurons to repress FSK-induced activity. Howev-
er, the molecular mechanisms underlying this GR-mediated
repression are still unknown. Guardiola-Diaz et al. suggested in
1996 that glucocorticoid repression occurs via interactions
between the GR and the cAMP-responsive element-binding
proteins [15], rather than via direct DNA binding of GR. In
contrast, Dorin et al. provided evidence, also in the same cell line as
used in present study, that the nGRE in the promoter is essential
for repression by glucocorticoids [13]. It would certainly be of
interest to study whether CREB phosphorylation status changes as
a consequence of GR activation at different time points, and test
the hypothesis that it is inversely related with the extent of GR
repression. However, while CREB-driven transcription is re-
pressed by glucocorticoids on the composite hCRH promoter, it is
unaffected on a 56CRE-containing promoter [18]. With the
possible caveat that the 56CRE may be not allow detection of
subtle changes in CREB function, these data point to gene/
promoter specificity of any direct CREB-GR interactions.
On the other hand, FSK-induced PKA can modulate glucocor-
ticoid signaling both on the composite hCRH and the exclusively
36GRE-containing promoters. Therefore, PKA activation can
determine the transcriptional outcome at glucocorticoid target genes,
Figure 2. Relative timing of DEX and FSK treatment determines efficacy of GR-dependent repression of CRH-promoter activity. (2A)
FSK-stimulation progressively induces the CRH-promoter activity in the Att20 cells over time. Co-treatment with DEX resulted in a repressed CRH-
activity. 2B) CRH-promoter activity expressed as percentage of maximal induction after 3 hours forskolin (FSK) treatment (filled bar). Simultaneous co-
treatment with DEX (open bar) resulted in a strong repression of the CRH-promoter activity. (2C) The repression induced by DEX in the co-treatment
group was set at 100%. All groups were treated for three hours with FSK. Different time of onset of the DEX treatment relative to the FSK treatment
results in a significant loss of repression when DEX treatment is started 10 minutes after FSK treatment (*). FSK treatment leads to a progressive
increase in CRH-luc promoter activity over a period of at least 5 hours (inset). Values represent group averages 6 SD.
doi:10.1371/journal.pone.0004327.g002
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that there is no cross-talk between the GR and CREB off the DNA
but that PKA activation modulates GR-mediated transcription by
changing e.g the phosphorylation status of coregulator proteins.
Chromatin immunoprecipitation assays should be used to test the
interactions between GR and (phospho-)CREB at the CRH
promoter, and demonstrate lack of direct GR-CREB interactions
at non-composite GRE-containing promoters.
An unexplained phenomenon is that, in contrast to the situation
in PVN, glucocorticoids induce, rather than repress, CRH gene
expression in the placenta and amygadala [2,22–24]. The opposite
effect of GR in these cells may rather relate to differential presence
of transcription factors or coactivators such as SRC1a [18,25]. One
principle difference in cellular context between CRH containing
cells in PVN and other tissues is that activation of the CRH gene in
the paraventricular cells often will be accompanied by increased
activation of the HPA axis, causing a quick rise in glucorticoid levels
and GR activation. However, current data should be interpreted in
the context of regulation of the CRH-promoter in the PVN, and do
not give insights in the mechanisms governing the cell-specific
effects of glucocorticoids on CRH expression.
It is well known that acute exogenous steroid treatment
effectively suppresses stress-induced expression of CRH mRNA
in rats [26]. However, the current study using a model system
shows that repression is markedly attenuated if GR activation is
initiated with as little as a 10 minutes delay. The critical time-
window for effective repression by glucocorticoids may have
interesting implications in the control of CRH expression in vivo.
The order of activation of both signaling pathways is variable, and
depends on the history of stress and glucocorticoid exposure, as
well as the circadian and ultradian pulsatility of glucocorticoid
levels [27]. Therefore, it is likely that effective GR-mediated
repression of the stress-induced CRH mRNA expression will only
occur in specific situations. We conclude that the differences in
timing of stimulatory and repression signals are of consequence for
adaptation of the organism to stress.
Materials and Methods
Reporter assays
0.1610
6 cells were transiently transfected in 24-wells plate using
Lipofectamine 2000 (Invitrogen, Breda, The Netherlands) accord-
ing to the manufacturer’s instructions. Per well, 200 ng of the
hCRH-luc reporter plasmid [18] or the 36GRE containing
TAT3-luc reporter were transfected. The day after transfection,
the cells were treated with 10 mM forskolin (Calbiochem,
Darmstadt, Germany) and/or 0.1 mM of the synthetic glucocor-
ticoid dexamethasone (DEX) and assayed for luciferase activity.
Figure 3. Translocation of the GR occurs within 10 minutes after treatment. (3A) Time course of GR-ir in different treatment groups. DEX
alone and FSK + DEX co-treatment, but not FSK alone show nuclear GR staining after 10 minutes treatment. (3B) Control IgG staining show specificity
of the GR-specific antibody. (3C) Nuclear quantification of GR-ir after 10 minutes treatment. Values represent average 6SEM.
doi:10.1371/journal.pone.0004327.g003
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repeated at least three times. Statistical analysis was performed
using one way analysis of variance (ANOVA) and statistical
significance (*) was determined with Tukey’s multiple comparison
tests with p,0.05.
Immunofluorescent staining of the GR
A day prior stimulation, 30610
3 AtT-20 cells were grown in
chamber slides. Following stimulation, cells were fixed in 4%
paraformaldehyde, permeabilized with Triton X-100 and blocked
with 5% normal goat serum. Cells were incubated with a GR-
specific antibody (M20; dilution 1:500; Santa Cruz biotechnolo-
gies) during 60 minutes, washed and subsequently incubated for
60 minutes with a secondary goat anti-rabbit Alexa Fluor 488
antibody (dilution 1:750; Invitrogen, Breda, The Netherlands).
After incubation, cells were washed and counterstained for 10 min
with Hoechst 33528. All sections were embedded in polyaqua-
mount (Polysciences, Inc.) and visualized with an immunofluores-
cence microscope (Leica DM6000). Control cells were incubated
with equal amounts of non-immune rabbit serum (Santa Cruz),
which was used as substitute for the primary antibodies. Nuclear
immunoreactivity was measured using ImageJ 1.32j software
(NIH, USA).
Author Contributions
Conceived and designed the experiments: SvdL OCM. Performed the
experiments: SvdL. Analyzed the data: SvdL OCM. Wrote the paper:
SvdL ERdk OCM.
References
1. Liu Y, Kamitakahara A, Kim AJ, Aguilera G (2008) Cyclic adenosine 39,59-
monophosphate responsive element binding protein phosphorylation is required
but not sufficient for activation of corticotropin-releasing hormone transcription.
Endocrinology 149: 3512–3520.
2. Swanson LW, Simmons DM (1989) Differential steroid hormone and neural
influences on peptide mRNA levels in CRH cells of the paraventricular nucleus:
a hybridization histochemical study in the rat. J Comp Neurol 285: 413–435.
3. Zoeller RT, Tan SW, Tyl RW (2007) General background on the hypothalamic-
pituitary-thyroid (HPT) axis. Crit Rev Toxicol 37: 11–53.
4. de Kloet ER, Joels M, Holsboer F (2005) Stress and the brain: from adaptation
to disease. Nat Rev Neurosci 6: 463–475.
5. Van LP, Spengler DH, Holsboer F (1990) Glucocorticoid repression of 39,59-
cyclic-adenosine monophosphate-dependent human corticotropin-releasing-
hormone gene promoter activity in a transfected mouse anterior pituitary cell
line. Endocrinology 127: 1412–1418.
6. Spengler D, Rupprecht R, Van LP, Holsboer F (1992) Identification and
characterization of a 39,59-cyclic adenosine monophosphate-responsive element
in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol
6: 1931–1941.
7. Kraus J, Hollt V (1995) Identification of a cAMP-reponsive element on the
human proopiomelanocortin gene upstream promoter. DNA and Cell Biology
14: 103–110.
8. Drouin J, Trifiro MA, Plante RK, Nemer M, Eriksson P, et al. (1989)
Glucocorticoid receptor binding to a specific DNA sequence is required for
hormone-dependent repression of pro-opiomelanocortin gene transcription. Mol
Cell Biol 9: 5305–5314.
9. Hagiwara M, Brindle P, Harootunian A, Armstrong R, Rivier J, et al. (1993)
Coupling of hormonal stimulation and transcription via the cyclic AMP-
responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol
Cell Biol 13: 4852–4859.
10. Delghandi MP, Johannessen M, Moens U (2005) The cAMP signalling pathway
activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cell Signal 17:
1343–1351.
11. Wolfl S, Martinez C, Majzoub JA (1999) Inducible binding of cyclic adenosine
39,59-monophosphate (cAMP)-responsive element binding protein (CREB) to a
cAMP-responsive promoter in vivo. Mol Endocrinol 13: 659–669.
12. Kovacs KJ, Sawchenko PE (1996) Sequence of stress-induced alterations in
indices of synaptic and transcriptional activation in parvocellular neurosecretory
neurons. J Neurosci 16: 262–273.
13. Malkoski SP, Handanos CM, Dorin RI (1997) Localization of a negative
glucocorticoid response element of the human corticotropin releasing hormone
gene. MolCell Endocrinol 127: 189–199.
14. Malkoski SP, Dorin RI (1999) Composite glucocorticoid regulation at a
functionally defined negative glucocorticoid response element of the human
corticotropin-releasing hormone gene. Mol Endocrinol 13: 1629–1644.
15. Guardiola-Diaz HM, Kolinske JS, Gates LH, Seasholtz AF (1996) Negative
glucorticoid regulation of cyclic adenosine 39,5 9-monophosphate-stimulated
corticotropin-releasing hormone-reporter expression in AtT-20 cells. Mol
Endocrinol 10: 317–329.
16. Pearce D, Matsui W, Miner JN, Yamamoto KR (1998) Glucocorticoid receptor
transcriptional activity determined by spacing of receptor and nonreceptor DNA
sites. J Biol Chem 273: 30081–30085.
17. Shipston MJ, Antoni FA (1992) Inactivation of early glucocorticoid feedback by
corticotropin-releasing factor in vitro. Endocrinology 130: 2213–2218.
18. van der Laan S, Lachize SB, Vreugdenhil E, de Kloet ER, Meijer OC (2008)
Nuclear receptor coregulators differentially modulate induction and glucocor-
ticoid receptor-mediated repression of the corticotropin-releasing hormone gene.
Endocrinology 149: 725–732.
19. Weigel NL, Moore NL (2007) Steroid receptor phosphorylation: a key
modulator of multiple receptor functions. Mol Endocrinol 21: 2311–2319.
20. Liu W, Wang J, Sauter NK, Pearce D (1995) Steroid receptor heterodimeriza-
tion demonstrated in vitro and in vivo. ProcNatlAcadSciUSA 92: 12480–12484.
21. Winnay JN, Xu J, O’Malley BW, Hammer GD (2006) Steroid receptor
coactivator-1-deficient mice exhibit altered hypothalamic-pituitary-adrenal axis
function. Endocrinology 147: 1322–1332.
22. Makino S, Gold PW, Schulkin J (1994) Effects of corticosterone on CRH mRNA
and content in the bed nucleus of the stria terminalis; comparison with the effects
in the central nucleus of the amygdala and the paraventricular nucleus of the
hypothalamus. Brain Res 657: 141–149.
23. Watts AG (2005) Glucocorticoid regulation of peptide genes in neuroendocrine
CRH neurons: a complexity beyond negative feedback. Front Neuroendocrinol
26: 109–130.
Figure 4. The FSK induced GR resistance is specific for the CRH
promoter. TAT3-luc (GRE-containing promoter) activity is expressed as
percentage of maximal induction after 4 hours DEX treatment (filled
bar; t=0). All groups (hatched bars) were treated for 4 hours with DEX
and only the time of onset of FSK treatment was different. Forskolin
treatment strongly enhanced the transcriptional rate of GR at all time
points (# indicates significantly different from DEX group with p,0.05).
Pre-treatment with FSK resulted in the highest potentiation of the GR
transcriptional rate.
doi:10.1371/journal.pone.0004327.g004
Timing of CRH Repression
PLoS ONE | www.plosone.org 5 January 2009 | Volume 4 | Issue 1 | e432724. King BR, Nicholson RC (2007) Advances in understanding corticotrophin-
releasing hormone gene expression. Front Biosci 12: 581–590.
25. King BR, Smith R, Nicholson RC (2002) Novel glucocorticoid and cAMP
interactions on the CRH gene promoter. Mol Cell Endocrinol 194: 19–28.
26. Ginsberg AB, Campeau S, Day HE, Spencer RL (2003) Acute glucocorticoid
pretreatment suppresses stress-induced hypothalamic-pituitary-adrenal axis
hormone secretion and expression of corticotropin-releasing hormone hnRNA
but does not affect c-fos mRNA or fos protein expression in the paraventricular
nucleus of the hypothalamus. J Neuroendocrinol 15: 1075–1083.
27. Windle RJ, Wood SA, Lightman SL, Ingram CD (1998) The pulsatile
characteristics of hypothalamo-pituitary-adrenal activity in female Lewis and
Fischer 344 rats and its relationship to differential stress responses. Endocrinol-
ogy 139: 4044–4052.
28. Chen XN, Zhu H, Meng QY, Zhou JN (2008) Estrogen receptor-alpha and -
beta regulate the human corticotropin-releasing hormone gene through similar
pathways. Brain Res 1223: 1–10.
29. Lalmansingh AS, Uht RM (2008) Estradiol regulates corticotropin-releasing
hormone gene (crh) expression in a rapid and phasic manner that parallels
estrogen receptor-alpha and -beta recruitment to a 39,59-cyclic adenosine 59-
monophosphate regulatory region of the proximal crh promoter. Endocrinology
149: 346–357.
Timing of CRH Repression
PLoS ONE | www.plosone.org 6 January 2009 | Volume 4 | Issue 1 | e4327